Yuji Matsuzaki Selected Research

Therapeutics

8/2004	N-octyl-beta-valienamine up-regulates activity of F213I mutant beta-glucosidase in cultured cells: a potential chemical chaperone therapy for Gaucher disease.
12/2003	Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yuji Matsuzaki Research Topics

Disease

3	Infections 01/2022 - 03/2006
1	Gaucher Disease (Gaucher's Disease) 08/2004
1	Sphingolipidoses (Sphingolipidosis) 08/2004
1	Mucopolysaccharidosis IV (Morquio Syndrome) 12/2003
1	Lysosomal Storage Diseases (Lysosomal Storage Disease) 12/2003
1	GM1 Gangliosidosis (Gangliosidosis GM1) 12/2003

Drug/Important Bio-Agent (IBA)

2	Antiviral Agents (Antivirals)IBA 01/2022 - 01/2008
2	N-octyl-beta-valienamineIBA 08/2004 - 12/2003
1	EnzymesIBA 01/2008
1	L870810IBA 01/2008
1	elvitegravirIBA 01/2008
1	QuinolonesIBA 03/2006
1	Anti-Bacterial Agents (Antibiotics)IBA 03/2006
1	beta-GlucosidaseIBA 08/2004
1	Galactose (Galactopyranose)FDA LinkGeneric 12/2003

Therapy/Procedure

2	Therapeutics 08/2004 - 12/2003